GLP-1 Weight Loss Peptide Market Surge: Efficacy, Brand Competition & Supply Chain Insights
Title: GLP-1 Weight Loss Peptide Market Surge: Efficacy, Brand Competition & Supply Chain Insights Abstract (148 words): The GLP-1 weight loss peptide market is experiencing explosive growth, driven by proven efficacy in achieving 15-20% body weight reduction, surpassing earlier analogs. Brand competition intensifies between Novo Nordisk’s semaglutide (Wegovy/Ozempic) and Eli Lilly’s tirzepatide (Mounjaro/Zepbound), with the latter demonstrating superior glycemic control via dual GIP/GLP-1 agonism. Supply chain bottlenecks persist due to API scarcity and cold-chain logistics requirements (2-8°C). Technically, peptides offer high specificity but suffer from short half-lives and oral bioavailability challenges. Market trends indicate a shift toward oral formulations and next-generation triple agonists. For buyers, verifying GMP-certified manufacturing facilities (FDA/EMA audits) and third-party HPLC purity assays (>98%) is critical. The sector’s future hinges on scalable synthesis and regulatory harmonization, with the global peptide therapeutics market projected to exceed $50 billion by 2030.